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CCNU and related nitrosoureas are
effective in the treatment of a number of
different cancers in man. including lym-
phomata, brain tumours and melanoma.
In some of their properties, for example
cross resistance and reactivity to thiol
groups and to nitrobenzyl pyridine, they
resemble the alkylating agents, and be-
cause they decompose chemically to
alkylating entities, it has been suggested
that the two classes of compounds act by
a common mechanism (Schabel et al.,
1963; Pittillo, Narkates and Burns, 1964;
Gale, 1965; Montgomery et al., 1967;
Wheeler and Chumley, 1967; Wheeler and
Bowdon, 1965). There are, however,
many differences between the two types
of agent. The majority of the anti-
tumour nitrosoureas have only a single
alkylating function whereas in the classic
alkylating agent series the presence of at
least two functional arms is essential for
anti-tumour activity. It is also known
that tumours resistant to alkylating
agents are not necessarily cross-resistant
to 1,3-bis(2-chloroethvl)-1-nitrosourea
(BCNIJ) (Selawrv and Hansen, 1972)
while the TLX5 lymphoma, which is
highly sensitive to BCNU, does not res-
pond at all to alkylating agents (Audette
et al., 1973). The nitrosoureas also pro-
long the S phase of cells in cycle, an effect
quite different from the action of cyclo-
phosphamide and other bifunctional alky-
lating agents (Bray et al., 1971; Young,
1969; Shirakawa and Frei, 1970).
In studies at the cellular level (Cheng
et al., 1972) using 14C-labelled CCNU, it
has been shown that the cyclohexyl
moiety binds extensivelv to protein but
negligibly to nucleic acids, whereas the
ethylene moietybinds only to a small ex-
tent to both the nucleic acids and proteins.
The results presented here, using the
TLX5 lymphoma and a line with acquired
resistance to BCNU, show essentially
similar results and also demonstrate that
the nuclear proteins are particularly sus-
ceptible to attack by the cyclohexyl
moiety of CCNU.
MATERIALS AND METHODS
The TLX5 lymphoma was maintained by
weekly intraperitoneal passage of 105 ascites
cells in CBA/LAC female mice. A line with
acquired resistance to BCNU was obtained
by Neekly treatment of the tumour bearing
animals wAith increasing dose levels of the
nitrosourea as previously described (Audette
et al., 1973).
1-(2-Chloroethyl)-3-cyclohexyl- 1-nitro-
sourea (NSC 79057), the 14C-cyclohexyl deri-
vative (specific activity 12-62 mCi/mmol) and
the derivative labelled with 14C in the carbon
atoms of the 2-chloroethyl moiety (specific
activity 9.94 mCi/mmol) were kindly sup-
plied by Dr H. Wood, Drug Research and
Development, Division of Cancer Treatment,
National Cancer Institute, Washington.T. A. CONNORS AND J. R. HARE
The in vitro concentration of BCNU,
CCNU and chlorambucil to kill greater than
99.99% tumour cells was determined by
incubating washed TLX5 ascites cells in
horse serum: TC 199, 40: 60 (v/v) for 2 h at
37°C in the presence of a range of concentra-
tions of each drug. The cell kill was esti-
mated by injection ofthe incubated cells into
mice and recording of the survival time as
previously described (Ball et al., 1966).
The distribution of CCNU was deter-
mined by incubating washed TLX5 ascites
cells in TC 199 at a concentration of 15.0 x
106 cells/ml at 37°C. Thirty min later,
labelled CCNU (1 ,uCi/5 ml cell suspension)
was added at a concentration of40 ,tg/ml and
the incubation continued for 1 h. Total
intracellular material was estimated by
centrifuging the cells at 300 g for 5 min,
dissolving the cell pellet in 10% TEH
(tetraethylammonium hydroxide) and meas-
uring radioactivity in a Packard scintillation
counter model 3375. The DNA, RNA
nuclear and cytoplasmic proteins were iso-
lated from the centrifuged cells by the
method of Pascoe and Roberts (1974).
RESULTS AND DISCUSSION
The sensitivity of the two lines of the
TLX5 lymphoma is shown in Table I.
Both nitrosoureas are effective against the
sensitive tumour at concentrations that
TABLE I. Sensitivity ofTLX5 Lymphonia
Cells in vitro
Treatment
BCNU
CCNU
Chlorambucil
Dose required to give
>99 99% cell kill (,ug/ml)
AA
Sensitive Resistant
tumour tumour
8 32
8 32
40 20
can be attained in vivo, in contrast to
chlorambucil which is less effective. This
confirms the finding in whole animals that
the tumour is sensitive to nitrosoureas but
quite unresponsive to nitrogen mustards
even at maximum tolerated dose levels
(Audette et al., 1973). There is a four-
fold resistance to BCNUT and a similar
level of cross-resistance to CCNU. How-
ever, the resistant line shows an increased
sensitivity to chlorambucil and is a further
example of the collateral sensitivity seen
with manv resistant tumour lines (Schmid
and Hutchison, 1972).
Table II shows the distribution of the
drug intra- and extracellularly, and the
amount bound to the cellular TCA
(trichloroacetic acid) insoluble material,
mainly protein and nucleic acids. The
14C-ethylene labelled derivative is distri-
buted uniformly throughout the medium,
since the 3.8% oflabel found intracellular-
ly is the approximate percentage volume
of the cells in the medium. The cyclo-
hexvl labelled nitrosourea attains a higher
intracellular concentration, which could
be due to breakdown of the agent outside
cells and the more efficient uptake of the
cyclohexyl moiety, or to the trapping of
the moiety intracellularlv because of its
greater covalent reaction with cell con-
stituents.
Despite the four-fold difference in
sensitivity to CCNU, there was no sig-
nificant difference in the distribution of
the compound in the sensitive and
resistant tumour lines.
Table III shows the binding ofthe two
labelled derivatives to various macro-
TABLE II.-Distribution of 14C Labelled CCNU
Sensitive tumour Resistant tumour
14C-ethylene 14C-cyclohexyl '4C-ethylene 14C-cyclohexyl
Fraction (%) (%) (%) (%)
Total intracellular radioactivity 3-8 14- 1 6-6 14-5
Total extracellular radioactivity 96-2 85-9 93-4 85-5
TCA insoluble 15-4 29-0 14-0 30 5
TCA soluble 84-6 71-0 86-0 69-5
Results are expressed as a percentage of total radioactivity. The TCA soluble and insoluble fractions are
expressed as a percentage of the total intracellular radioactivity. Results are the averages of 3
determinations.
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TABLE III.-Binding of 14C-labelled CCNU to Macromolecutlar Fractions of the
TLX5 Lymphoma
Sensitive tumour Resistant tumour
(d/min/mg dry weight) (d/min/mg dry weight)
K-A AA
Fraction 14C-ethylene '4C-cyclohexyl 14C-ethylene '4C-cyclohexyl
DNA 88-5± 8-7 54-8± 13-5 56-9± 12-4 74-3± 12-3
RNA 227-7±119-6 1278-2± 326-3 137-9±116-1 1311-0± 546-7
Total protein 410-0± 69 0 14768-0±2590-2 452-6± 74-5 10079-2± 997 0
Cytoplasmic proteinl 135-4± 38-2 6368-3±1138-1 236-6± 98-6 5454- 8± 451- 7
Nuclear protein 378-3 ± 86-4 15883-6±3342-7 513-8±230 9 14510-0±1800-1
The results obtained with the 14C-ethylene-labelled compound have been corrected to a specific activity
of 12-62 mCi/mmol in order to be directly comparable with the 14C cyclohexyl labelled derivative. Each
result is the mean from 3 separate determinations.
molecules. It is clear that the 14C-cyclo-
hexyl derivative has a particular affinity
for protein, especially the nuclear protein
fraction. These results are essentially
similar to those of Cheig et al. (1972)
except that the amount of drug bound to
RNA in these experiments is appreciably
higher. Analysis of the RNA fraction
showed it to contain less than 1% protein
and excludes the possibility that the high
labelling is an artefact due to contamina-
ting protein. The 14C-ethylene labelled
material, in contrast, showed only a very
low degree of binding to any fraction.
The results therefore confirm that BCNU
reacts predominantly by carbamoylation
of lysine residues of proteins following
chemical breakdown of the molecule to
release cyclohexyl isocyanate (Cheng et al.,
1972; Schmall et al., 1973). Carbamoyla-
tion of protein would explain the higher
radioactivity associated with the nuclear
protein fraction compared with cyto-
plasmic, because ofthe high concentration
oflysine rich protein in the former.
Once again, no difference was found in
the amount of drug bound to the various
macromolecules of the sensitive and res-
istant tumour lines.
Although these results show clearly
that the majority of the reaction taking
place in cells after administration of
CCNU involves carbamoylation reactions,
this cannot be the sole mechanism of
action since the active carbamoylating
entity, cyclohexyl isocyanate, while hav-
ing some properties in common with
CCNU is not an effective anti-cancer agent
in vivo (Oliverio, 1973). However, the
high level ofreaction with nuclear protein,
probably histone, is ofinterest since it has
been claimed that reaction with histone
protein is important in the mechanism of
action of both alkylating agents and alkyl
nitrosamines (Riches and Harrap, 1973;
Alonso and Arnold, 1974; Bhattacharya
and Schultz, 1974).
The mnechanism of action of the anti-
tumour chloroethylnitrosoureas is thus
still obscure but it is possible that its
action is a complex one involving both
inhibition of enzymes and structural
proteins by carbamoylation and alkyla-
tion of essential macromolecules.
This work was supported by grants to
the Chester Beatty Research Institute
(Institute of Cancer Research, Royal
Cancer Hospital) from the MIedical Re-
search Council (Grant No. 973/787/K) and
the award of a Medical Research Council
Studentship to one of us (J.H.).
REFERENCES
ALONSO, A. & ARNOLD, H. P. (1974) Stimulation of
Amino Acids Incorporation into Rat Liver
Nonhistone Chromatin Proteins after Treatment
with Diethylnitrosamine. FEBS Letters, 41, 8.
ATTDETTE, R. C. S., CONNORS, T. A., MANDEL, H. G.,
MERAr, K. & Ross, W. C. J. (1973) Studies on the
Mechanism of Action of the Tumour Inhibitory
Triazenes. Biochem. Pharmac., 22, 1855.
BALL, C. R., CONNORS, T. A., DOUBLE, J. A.,
ITJHAZY, V. & WHISSON, M. E. (1966) Comparison
of Nitrogen Mustard Sensitive and Resistant
Yoshida Sarcomas. Int. J. Cancer, 1, 319.
BHATTACHARYA, R. K. & SCHIJLTZE, M. 0. (1974)
Protective Effects of Histones against Drug
Induced Alterations of Deoxyribonucleic Acid in
Thymus Chromatin. Biochem. Pharmac., 23,
1519.480 T. A. CONNORS AND J. R. HARE
BRAY, D. A., DE VITA, V. T., ADAMSON, R. H. &
OLIVERIO, V. T. (1971) Effects of 1-(2-chloro-
ethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC
79037) and it3 Degradation Products on Pro-
gression of L1210 Cells through the Cell Cycle.
Cancer Chemother. Rep., 55, 215.
CHENG, C. J., FUJIMURA, S., GRUNBERGER, D. &
WEINSTEN, I. B. (1972) Interaction of 1-(2-
chloroethyl)-3-cyclohexyl- 1-nitrosourea (NSC
79037) with Nucleic Acids and Protoins in vivo
and in vitro. Cancer Res., 32, 22.
GALE, G. R. (1965) Effect of 1,3-bis (2-cbloroethyl)-
1-nitrosourea on Saccharomyces cereVisiae. Proc.
Soc. exp. Biol. Med., 119, 1004.
MONTGOMERY, J. A., JAMES, R., MCCALEB, G. &
JOHNSTON, T. P. (1967) The Modes of Decompo-
sition of 1,3-bis (2-chloroethyl)-1-nitrosourea and
Related Compounds. J. med. Chenz., 10, 668.
OLIVERIO, V. T. (1973) Toxicology and Pharma-
cology of the Nitrosoureas. Cancer Chemother.
Rep., 4 (3), 13.
PASCOE, J. M. & ROBERTS, J. J. (1974) Interactions
between Mammalian Cell DNA and Inorganic
Platinum Compounds. II. Interstrand Cross-
linking of Isolated and Cellular DNA by Platinum
(IV) Compounds. Biochem. Pharmac., 23, 1345.
PITTILLO, R. F.. NARKATES, A. J. & BURNS, J.
(1964) Microbiological Evaluation of 1,3-bis(2-
chloroethyl)-l-nitrosourea. CancerRes., 24, 1222.
RICHES, P. G. & HARRAP, K. R. (1973) Some Effects
of Chlorambucil on the Chromatin of Yoshida
Ascites Sarcoma Cells. Cancer Res., 33, 389.
SCHABEL, F. M., JOHNSTON, T. P., MCCALEB, G. S.,
MONTGOMERY, J. A., LASTER, W. R. & SKIPPER,
H. E. (1963) Experimental Evaluation of Poten-
tial Anti-cancer Agents. VIII. Effects of Certain
Nitrosoureas on Intracerebral L1210 Leukemia.
Cancer Res., 23, 725.
SCHMALL, B., CHENG, C. J., FUJIMURA, S., GERSTEN,
N., GRUNBERGER, D. & WEINSTEIN, I. B. (1973)
Modification of Proteins by 1-(2-chloroethyl)-3-
cyclohexyl-l-nitrosourea (NSC 79037) in vitro.
Cancer Res., 33, 1921.
SCHMID, F. A. & HUTCHINSoN, D. J. (1972) Collateral
Sensitivity of Resistant Lines of Mouse Leuk-
emias L1210 and L5178Y. Cancer Res., 32, 808.
SELAWRY, 0. S. & HANSEN, H. H. (1972) Superiority
of CCNU (1-(2-chloroethyl)-3-cyclohexyl- 1-nitro-
sourea; NSC 79037) over BCNU (1,3-bis(2-chloro-
ethyl)-1-nitrosourea; NSC 409962) inTreatment of
advanced Hodgkin's Disease. Proc. Am. Ass.
Cancer Res., 13, 46.
SHIRAKAWA, S. & FREI, E. (1970) Comparative
Effects of the Anti-tumor Agents 5(dimethyltri-
azeno)imidazole-4-carboxamide and 1,3-bis(2-
chloroethyl)- 1-nitrosourea on cell cycle of
L1210 Leukemia cells in vivo. Cancer Res., 30,
2173.
WHEELER, G. P. & BOWDEN, B. J. (1965) Some
Effects of 1,3-bis(2-chloroethyl)-1-nitrosourea
Upon the Synthesis of Protein and Nucleic Acids
in vivo and in vitro. Cancer Res., 25, 1770.
WHEELER, G. P. & CHUMLEY, S. (1967) Alkylating
Activity of 1,3-bis(2-chloroethyl)-1-nitrosourea
and Related Compounds. J. med. Chem., 10, 259.
YOUNG, R. C. (1969) Changes in the DNA Synthetic
Phase of the Cell Cycle of Leukemia L1210
Induced by the Chemotherapeutic Agents,
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and
Cyclophosphamide (CTX). Proc. Am. Ass. Can-
cer Res., 10, 102.